featured
Niraparib Plus Nivolumab or Niraparib Plus Ipilimumab for Platinum-Sensitive Advanced Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
Lancet Oncol 2022 Jul 07;[EPub Ahead of Print], KA Reiss, R Mick, U Teitelbaum, M O'Hara, C Schneider, R Massa, T Karasic, R Tondon, C Onyiah, MK Gosselin, A Donze, SM Domchek, RH VonderheideFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.